Market Research Logo

Pharmaceuticals Market Research Reports & Industry Analysis

The pharmaceutical industry is directly impacted by the research conducted with prescription drugs, vaccines, and OTC drugs being manufactured based on findings from the study of life sciences. Clinical trials are conducted to ensure that products being developed are tested on how well they work on individuals affected by the diseases or conditions they are created to treat. The market research available can provide investors and analysts credible information on the direction of pharmaceuticals, anesthesia, drug delivery, pricing, regulations and policy being developed to ensure that knowledgeable and informed decisions are made regarding industry direction.
...Show More ...Show Less


Pharmaceuticals Industry Research & Market Reports

  • Germany Diabetes Market Report: 2019 - 2024

    ... future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in Germany. The research study serves as an exceptional tool to understand the epidemiology, market trends, therapeutic structure, competitive structure and the outlook ... Read More

  • Antioxidants Industry Forecasts - China Focus

    ... capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is ... Read More

  • Europe Glucose Monitoring System Market Forecast 2019-2027

    ... of 32.91% over the forecast period of 2019-2027. The Europe Self-Monitoring of Blood Glucose (SMBG) market is expected to rise from $XX million in 2018 to $XX million by 2027, at a CAGR of 5.42% ... Read More

  • Vitamin C and Derivatives Companies in China

    ... pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing ... Read More

  • Analgesics in Latin America

    ... and the wider availability of generic remedies are expected to contribute positively to overall sales, targeting consumers who look for the latest and fastest solutions and also those who are more price conscious. Euromonitor International’s ... Read More

  • Anagelsics in Latin America

    ... and the wider availability of generic remedies are expected to contribute positively to overall sales, targeting consumers who look for the latest and fastest solutions and also those who are more price conscious. Euromonitor International’s ... Read More

  • Healthcare Distribution Market by Type (Pharmaceutical (Brand-name, Generic, OTC, Vitamins), Medical Device, Biopharmaceutical (Vaccines, Monoclonal Antibodies)), End User (Retail Pharmacies, Hospital Pharmacies) - Global Forecasts to 2024

    ... grow at a CAGR of 6.5% during the forecast period of 2019 to 2024” The healthcare distribution market is projected to reach USD 1,048.4 billion by 2024 from USD 765.4 billion in 2019, at a ... Read More

  • Free From in Australia

    ... about the benefits of vegan alternatives. The premiumisation of free from gluten and similar categories has also encouraged growth in such products. Casalare, an Australian-owned manufacturer of organic, premium, gluten-free pastas, baking mixes and speciality ... Read More

  • Health and Wellness in Australia

    ... have a health positioning, such as an “all natural” claim, have an influence on their purchasing decision. For example, Euromonitor International’s Global Consumer Trends Survey 2017 found that an “all natural” claim was an influential ... Read More

  • Skin Care in Mexico

    ... of versions and delivery formats contributed to diversification, propelling its positive performance. New brands in the category, such as Animalz, Freeman, Look Beauty, Cutis Femme and Mumuso, to mention just a few, also added to ... Read More

  • Amphastar Pharmaceuticals Inc (AMPH) - Financial and Strategic SWOT Analysis Review

    ... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More

  • AVEO Oncology Inc (AVEO) - Financial and Strategic SWOT Analysis Review

    ... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More

  • Athersys Inc (ATHX) - Financial and Strategic SWOT Analysis Review

    ... you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand ... Read More

  • DURECT Corp (DRRX) - Financial and Strategic SWOT Analysis Review

    ... you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand ... Read More

  • Turkey Pharmaceuticals & Healthcare Q3 2019

    ... Health TransformationPlan. However, we highlight that increasing macro risks, emphasised by the lira sell-off in August 2018, will increasingly placedownside risks to this expansionary fiscal outlook, leading to growth deceleration over the long term. Moreover, ... Read More

  • Mauritius Pharmaceuticals & Healthcare Q3 2019

    ... supportgrowing health spending. Pharmaceutical imports will continue to account for most of the market, given limited local drugmanufacturing capacity. The gradual strengthening of drug sale regulation will improve drug use safety and the operatingenvironment. Over ... Read More

  • Tunisia Pharmaceuticals & Healthcare Q3 2019

    ... will challenge foreign investment into the sector. Highlightingthe market's long-term potential, some multinational drugmakers have shown their willingness to do business in the countryalthough the majority choose to operate indirectly to minimise the risks involved. Read More

  • Nigeria Pharmaceuticals & Healthcare Q3 2019

    ... despite it's elevatedrisk profile. Long-term opportunities are supported by robust fundamentals such as a large market size and expandingpopulation. The implementation of governmental initiatives aim to drive growth in the sector over the coming years. Read More

  • South Korea Pharmaceuticals & Healthcare Q3 2019

    ... for drugmakers. The aggressive drug pricing policies will continue to weigh on the market potential.Nonetheless, the government will remain committed towards supporting healthcare innovations and personalised medicaltreatment development, and pharmaceutical exports will continue to grow. Read More

  • United States Pharmaceuticals & Healthcare Q3 2019

    ... Private health insurance is not expected to contribute significantly togrowth in prescription drug expenditure. Out-of-pocket spending on prescription drugs is forecast to become more common due tothe removal of the penalty for not having insurance. Read More

  • Spain Pharmaceuticals & Healthcare Q3 2019

    ... generic drug sector and the government’s continuedfocus on cost-containment measures targeting prescription drug expenditure. These trends, along with a subdued economicoutlook, make Spain one of the more challenging markets in Western Europe for multinational drugmakers. Read More

  • Thailand Pharmaceuticals & Healthcare Q3 2019

    ... into its domestic pharmaceutical industry and drugmakers will continue to be attracted to the high-growthmarket. However, given the low levels of affordability and poor access to healthcare, the market will mainly be suited to genericdrugmakers. Read More

  • Azerbaijan Pharmaceuticals & Healthcare Q3 2019

    ... marginal interest to major pharmaceutical players. Despite the scheduled roll-out of themandatory healthcare insurance programme, public sector funding is expected to remain lacking. The over-reliance ofpharmaceutical expenditure on out-of-pocket payments is an additional risk factor. Read More

  • Indonesia Pharmaceuticals & Healthcare Q3 2019

    ... their efforts to achieve universal healthcare coverage. However, some foreign players may remain wary of committingto the market due to the prevalence of counterfeit medicines, low per capital purchasing power and the uncertain funding base. Read More

  • Ethiopia Pharmaceuticals & Healthcare Q3 2019

    ... and healthcare markets will remain dependent on available finances andthe wider political and economic climate. Nevertheless, authorities are aiming to extend healthcare coverage and improve regionalservices, which is already attracting niche investment from Chinese companies. Read More

1 2 3 4 6 8 9 10